Is Anika Therapeutics Inc (NASDAQ:ANIK)’s Fuel Running Low? Reports Show More Sellers

May 16, 2018 - By Milton Kimbrough

Anika Therapeutics, Inc. (NASDAQ:ANIK) Logo

Investors sentiment decreased to 1.37 in Q4 2017. Its down 0.05, from 1.42 in 2017Q3. It dived, as 12 investors sold Anika Therapeutics, Inc. shares while 45 reduced holdings. 24 funds opened positions while 54 raised stakes. 12.26 million shares or 0.18% less from 12.29 million shares in 2017Q3 were reported.
Nelson Van Denburg & Campbell Wealth Mgmt Group Incorporated Ltd Co holds 8,575 shares or 0.1% of its portfolio. Magnetar Fin holds 0.01% of its portfolio in Anika Therapeutics, Inc. (NASDAQ:ANIK) for 5,203 shares. Victory Management Inc invested 0% of its portfolio in Anika Therapeutics, Inc. (NASDAQ:ANIK). Seaward Management L P reported 32,300 shares. Metropolitan Life Ny holds 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK) or 5,141 shares. Advisory Ser Networks Limited Liability Company accumulated 0% or 88 shares. Btim Corporation holds 0.2% of its portfolio in Anika Therapeutics, Inc. (NASDAQ:ANIK) for 250,148 shares. Jpmorgan Chase & holds 0% or 31,254 shares. Sei Invests holds 3,046 shares or 0% of its portfolio. 12,444 were reported by Credit Suisse Ag. Healthinvest Ab reported 13.04% in Anika Therapeutics, Inc. (NASDAQ:ANIK). Mcf Advisors Ltd has invested 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK). First Republic Invest Management Inc, California-based fund reported 42,690 shares. Bancorporation Of Montreal Can owns 0% invested in Anika Therapeutics, Inc. (NASDAQ:ANIK) for 2,781 shares. Dimensional Fund Advsr L P stated it has 0.02% of its portfolio in Anika Therapeutics, Inc. (NASDAQ:ANIK).

The stock of Anika Therapeutics Inc (NASDAQ:ANIK) registered an increase of 2.92% in short interest. ANIK’s total short interest was 1.20 million shares in May as published by FINRA. Its up 2.92% from 1.17M shares, reported previously. With 140,800 shares average volume, it will take short sellers 9 days to cover their ANIK’s short positions. The short interest to Anika Therapeutics Inc’s float is 8.36%.

The stock increased 4.82% or $1.84 during the last trading session, reaching $39.99. About 469,468 shares traded or 251.92% up from the average. Anika Therapeutics, Inc. (NASDAQ:ANIK) has risen 15.35% since May 16, 2017 and is uptrending. It has outperformed by 3.80% the S&P500.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company has market cap of $589.66 million. The firm develops, makes, and commercializes therapeutic products based on its proprietary hyaluronic acid technology. It has a 18.95 P/E ratio. The Company’s orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Ratings Coverage

Among 3 analysts covering Anika Therapeutics Inc (NASDAQ:ANIK), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Anika Therapeutics Inc had 4 analyst reports since December 28, 2017 according to SRatingsIntel. The firm earned “Market Perform” rating on Friday, February 23 by Barrington Research. First Analysis upgraded the stock to “Overweight” rating in Wednesday, January 24 report. Barrington Research upgraded the stock to “Outperform” rating in Friday, May 4 report.

More notable recent Anika Therapeutics, Inc. (NASDAQ:ANIK) news were published by: Nasdaq.com which released: “Mid-Afternoon Market Update: Dow Turns Positive; Anika Therapeutics Shares Fall Following Disappointing Q1 Results” on May 03, 2018, also Businesswire.com with their article: “Anika to Present at the 2018 Deutsche Bank Health Care Conference on May 8, 2018” published on April 24, 2018, Benzinga.com published: “The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap” on April 29, 2018. More interesting news about Anika Therapeutics, Inc. (NASDAQ:ANIK) were released by: Businesswire.com and their article: “Anika to Showcase Commercial and Pipeline Portfolio at 18th Bi-Annual European Society for Sports Traumatology …” published on May 08, 2018 as well as Seekingalpha.com‘s news article titled: “J&J cost cutting plan may pressure suppliers – Bloomberg” with publication date: April 17, 2018.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.